[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"myeloproliferative-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:myeloproliferative-disease":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,58,80],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":57},"100632842","energia-personalized-exercise-program-for-fatigue-in-patients-with-myeloproliferative-neoplasms-and-chronic-myeloid-leukemia-100632842",false,"NCT07518940","ENERGIA: Personalized Exercise Program for Fatigue in Patients With Myeloproliferative Neoplasms and Chronic Myeloid Leukemia","ENERGIA: Exercise in Rare Hematologic Diseases With Individualized and Adapted Management","ENERGIA","Inclusion Criteria:\n\nAge ≥18 years Confirmed diagnosis of myeloproliferative neoplasm (polycythemia vera, essential thrombocythemia, low-risk primary myelofibrosis) or chronic myeloid leukemia according to WHO criteria Clinical and therapeutic stability for at least 8 weeks prior to enrollment Presence of clinically relevant fatigue as assessed by validated disease-specific questionnaires General clinical condition compatible with participation in a supervised exercise program of at least moderate intensity Absence of contraindications to cardiopulmonary exercise testing No participation in structured exercise or rehabilitation programs within the previous 3 months Minimum hematological safety parameters (hemoglobin \\>10 g\u002FdL; platelets \\>100,000 × 10⁹\u002FL) Ability to understand and comply with study procedures Provision of written informed consent\n\nExclusion Criteria:\n\nUnstable cardiovascular conditions (including uncontrolled heart failure, recent myocardial ischemia, symptomatic ventricular arrhythmias, or unexplained syncope) Thrombotic or hemorrhagic events within the previous 3 months Active acute or chronic infections Severe orthopedic or neurological conditions limiting the ability to perform exercise or functional testing Severe systemic diseases (e.g., advanced renal or hepatic failure, active secondary malignancy, uncontrolled psychiatric disorders) Any clinical condition that, in the investigator's judgment, may compromise safety or adherence to the protocol Indication for a primary structured rehabilitation program based on physiatric evaluation","ALL","18 Years",{"count":20,"type":21},25,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study evaluates whether a personalized, supervised exercise program can improve fatigue and physical function in patients with myeloproliferative neoplasms (MPN) and chronic myeloid leukemia (CML). Although many patients achieve good disease control with modern therapies, they often experience persistent symptoms such as fatigue that significantly affect daily life.\n\nParticipants will take part in a 12-week exercise program that includes aerobic and resistance training, tailored to their individual fitness level and clinical condition. The program consists of two supervised sessions per week, along with additional home-based aerobic activity. Before and after the program, participants will undergo comprehensive assessments, including cardiopulmonary exercise testing, physical function tests, questionnaires on fatigue and quality of life, and blood sample collection.\n\nThe study aims to determine whether this type of exercise program is feasible and safe, and whether it can reduce fatigue and improve physical capacity, quality of life, and biological markers related to inflammation and metabolism. Participants will also be followed after the intervention to evaluate whether the benefits are maintained over time.",[27,28,29,30,31],"Myeloproliferative Disease","Polycythemia Vera","Thrombocythemia Essential","Myelofibrosis, Primary","Chronic Myeloid Leukemia (CML)",[33,34,35,36,37,38,39,40,41,42,43,44],"Myeloproliferative Neoplasms;","Chronic Myeloid Leukemia","Exercise Intervention","Cancer-Related Fatigue","Fatigability","Physical Activity","Cardiorespiratory Fitness","Quality of Life","physical exercise","Immunometabolism","Metabolomics","Feasibility","NOT_YET_RECRUITING","2026-04-01",{"date":48,"type":49},"2026-04-09","ACTUAL",{"date":51,"type":21},"2026-08-01",{"date":53,"type":21},"2027-12-31",{"name":55,"class":56},"Carmen Fava","OTHER",1,{"id":59,"slug":60,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":62,"acronym":4,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":64,"targetDuration":4,"studyType":66,"phases":4,"briefSummary":67,"conditions":68,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":57},"100608656","unveiling-the-germline-predisposition-to-myeloproliferative-neoplasms-100608656","NCT07204392","Unveiling the Germline Predisposition to Myeloproliferative Neoplasms","Inclusion Criteria:\n\n* A diagnosis of PV, ET, prePMF, overt PMF or MPN-U according to 2016 WHO criteria\n* Characterization of the MPN driver mutation performed at any moment before enrolment\n* diagnosis of MPN made when the patient was younger than 27 years old OR at least a second case of hematologic malignancies in first or second-degree relatives\n\nExclusion Criteria:\n\n* None",{"count":65,"type":21},313,"OBSERVATIONAL","The classic Ph-negative myeloproliferative neoplasms (MPN) are a group of clonal hematopoietic disorders caused by a dysregulated JAK\u002FSTAT signal transduction because of acquired somatic mutations of JAK2, CALR or MPL genes. They are sporadic diseases but there are several lines of evidence that support the role of germline factors in the pathogenesis of MPN: the existence of familial clustering, the presence of more than one clone in some patients, the known existence of common polymorphisms that cause predisposition to MPN.\n\nIn this study, we would like to define the germline predisposition to MPN.",[27,69],"Germline Mutation","RECRUITING","2025-09-24",{"date":73,"type":49},"2025-10-02",{"date":75,"type":49},"2022-06-27",{"date":77,"type":21},"2030-12-31",{"name":79,"class":56},"Fondazione IRCCS Policlinico San Matteo di Pavia",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":66,"phases":4,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":101},"100481811","evaluation-of-inflammatory-markers-in-ph-negative-myeloproliferative-neoplasms-impact-on-outcome-and-response-to-therapy-multicenter-retro-prospective-observational-study-the-infla-me-inflammation-in-myeloproliferative-disease-study-100481811","NCT05553873","Evaluation of Inflammatory Markers in ph Negative Myeloproliferative Neoplasms: Impact on Outcome and Response to Therapy. Multicenter Retro-prospective Observational Study. The INFLA-ME (INFLAmmation in Myeloproliferative Disease) Study.","Inclusion Criteria:\n\n* Age ≥ 18 years at the time of diagnosis of MPN Ph negative\n* Diagnosis of PV, ET, PMF or post PV and post ET MF, according to current WHO or IWG-MRT criteria (diagnosis since 2000)\n* Obtaining informed consent\n\nExclusion Criteria:\n\n* Life expectancy of less than 6 months\n* Accelerated phase myelofibrosis or MPN with signs of leukemic evolution","99 Years",{"count":88,"type":21},500,"This study aims to observe inflammatory biomarkers and their trend over the history of the disease in patients suffering from MPN Ph negative; it also wants to identify any correlations between the aforementioned biomarkers and disease outcomes, considering first of all the occurrence of thrombo-haemorrhagic events and the evolution in the accelerated \u002F blast phase of the disease, shedding light on new tools that can potentially guarantee a prompt and better risk stratification",[27,91],"Inflammatory Markers","2023-12-29",{"date":94,"type":49},"2024-01-02",{"date":96,"type":49},"2022-09-08",{"date":98,"type":21},"2026-12",{"name":100,"class":56},"University of Milano Bicocca",11]